Court denies Regeneron bid to halt copy of blockbuster eye drug

Biotech’s motion for preliminary injunction to prevent Eylea biosimilar rejected I Regeneron has filed multiple suits over rivals’ copies of aflibercept.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Regeneron sues Amgen over biosimilar version of blockbuster eye drug

16 January 2024 US biotech has launched multiple suits over alleged infringement of Eylea patents | Regeneron asks US court to block Amgen’s biosimilar before potential approval.

Americas

Regeneron targets almost 50 patents in suit against Sandoz

29 August 2024 Regeneron accused the Swiss pharma company of infringing a slew of patents related to Eylea and violating the BPCIA | Suit alleges that Sandoz failed to provide critical information during the approval process for its newly FDA-approved biosimilar | Sandoz “forced” Regeneron to guess which patents might be infringed.

More on this story

Big Pharma

Regeneron sues Amgen over biosimilar version of blockbuster eye drug

16 January 2024 US biotech has launched multiple suits over alleged infringement of Eylea patents | Regeneron asks US court to block Amgen’s biosimilar before potential approval.

Americas

Regeneron targets almost 50 patents in suit against Sandoz

More on this story

Big Pharma

Regeneron sues Amgen over biosimilar version of blockbuster eye drug

16 January 2024 US biotech has launched multiple suits over alleged infringement of Eylea patents | Regeneron asks US court to block Amgen’s biosimilar before potential approval.

Americas

Regeneron targets almost 50 patents in suit against Sandoz